Akums Drugs & Pharma
add_icon

Akums Drugs & Pharma

745.35
+15.25
(2.09%)
Market Cap
11,731.36 Cr
PE Ratio
39.31
Volume
8,43,398.00
Day High - Low
769.45 - 728.35
52W High-Low
756.85 - 409.30
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
11,731.36 Cr
EPS
16.67
PE Ratio
39.31
PB Ratio
3.47
Book Value
210.57
EBITDA
650.70
Dividend Yield
0.40 %
Industry
Healthcare
Return on Equity
7.70
Debt to Equity
0.04
Analyst Rating and Forecast
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
positive
Akums Drugs & Pharma reports consolidated net profit of ₹1,009.78 million in Q1FY27, up 56% YoY. Revenue rises 14% to ₹11,666.29 million led by CDMO segment.
neutral
Akums Drugs & Pharmaceuticals to host Q1FY27 earnings call on Aug 10, 2026. Management team including MDs Sanjeev Jain and Sandeep Jain will discuss un-audited results.
positive
Akums Drugs & Pharma subsidiary Pure and Cure acquires Oriflame India's manufacturing business for ₹56 crore. The deal includes plants in Roorkee and Noida, marking Akums' entry into color cosmetics.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,929.10
#1 4,62,855.71
38.67
#1 61,673.90
12.69
#1 11,565
26.53
51.77
8,492.00
2,25,435.92
75.10
11,067.00
13.95
2,568
65.50
73.18
4,849.00
1,84,440.37
86.72
13,886.20
20.34
2,138
3.28
51.57
1,463.60
1,18,236.24
35.15
29,044.60
2.24
3,870
-39.18
57.39
1,156.00
1,16,320.65
21.82
27,657.90
17.64
5,026
7.82
50.30
2,266.10
1,03,613.46
#1 18.74
29,038.90
#1 26.75
5,356
16.00
35.94
2,406.70
99,395.74
48.70
14,636.40
14.85
1,938
29.13
43.44
1,840.60
99,366.00
92.47
6,867.80
22.01
890
#1 123.93
79.60
1,189.30
99,267.19
30.34
35,058.60
3.90
4,158
-69.10
35.65
1,649.00
94,879.81
25.76
34,145.20
5.56
3,503
25.21
63.22
Growth Rate
Revenue Growth
7.61 %
Net Income Growth
-25.42 %
Cash Flow Change
153.91 %
ROE
-31.37 %
ROCE
-7.29 %
EBITDA Margin (Avg.)
17.03 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
978
1,188
1,093
955
1,026
1,050
1,030
1,081
1,051
1,050
1,194
1,193
1,197
Expenses
1,095
1,057
989
941
891
912
889
962
895
923
1,031
1,008
992
EBITDA
-117
131
103
14
135
138
141
120
156
127
163
185
205
Operating Profit %
-13 %
11 %
9 %
0 %
13 %
12 %
12 %
9 %
13 %
9 %
11 %
13 %
15 %
Depreciation
30
30
32
34
34
35
45
40
37
38
40
40
41
Interest
12
14
12
12
13
12
5
5
23
23
24
24
25
Profit Before Tax
-159
87
59
-33
88
92
91
75
96
66
100
121
139
Tax
29
54
-136
7
26
25
25
-75
31
23
32
40
38
Net Profit
-187
33
195
-40
61
67
66
150
65
43
68
81
101
EPS in ₹
-13.16
2.22
13.21
-2.89
4.21
4.37
4.26
9.64
4.15
2.66
4.33
5.53
6.53

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
2025
2026
Total Assets
2,078
2,167
3,069
3,267
3,516
4,113
5,447
Fixed Assets
645
904
1,021
1,097
1,191
1,397
1,456
Current Assets
1,250
1,157
1,864
1,879
1,941
2,275
3,560
Capital Work in Progress
57
17
31
103
195
163
177
Investments
6
20
0
0
0
0
0
Other Assets
1,371
1,226
2,017
2,066
2,130
2,553
3,814
Total Equity & Liabilities
2,078
2,167
3,069
3,267
3,516
4,113
5,447
Current Liabilities
730
580
1,272
1,266
1,211
894
1,095
Non Current Liabilities
627
700
1,172
1,278
1,585
156
1,021
Total Equity
721
887
625
723
721
3,064
3,331
Reserve & Surplus
721
884
608
689
681
3,016
3,283
Share Capital
1
1
14
29
29
31
31

Cash Flow

Cash Flow
2015
2016
2020
2021
2022
2023
2024
2025
2026
Net Cash Flow
-11
4
71
-70
33
-4
59
-10
285
Investing Activities
-150
-123
-190
-109
-235
-305
-331
-548
-930
Operating Activities
72
89
28
131
32
177
498
465
1,181
Financing Activities
66
37
233
-92
236
125
-108
73
34

Share Holding

% Holding
Feb 2024
Aug 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Jun 2026
Promoter
84.91 %
75.26 %
75.26 %
75.26 %
75.26 %
75.26 %
75.26 %
75.26 %
75.26 %
75.26 %
FIIs
0.00 %
5.32 %
7.34 %
6.36 %
5.77 %
4.24 %
2.28 %
1.15 %
1.37 %
1.91 %
DIIs
0.00 %
7.60 %
7.52 %
7.00 %
7.40 %
8.85 %
9.28 %
14.40 %
14.35 %
13.44 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
4.43 %
2.11 %
3.33 %
3.41 %
3.60 %
5.01 %
5.51 %
5.34 %
5.57 %
Others
15.09 %
7.38 %
7.77 %
8.05 %
8.16 %
8.05 %
8.18 %
3.68 %
3.68 %
3.82 %
No of Share Holders
8
1,38,205
57,531
68,410
69,366
69,424
75,365
76,869
72,589
70,289

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.41

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
09 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
09 Nov 2024 845.30 796.60
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 566.55 570.30
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 May 2025 546.50 566.05
18 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
18 Jul 2025 566.05 559.90
08 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 Aug 2025 513.90 490.80
13 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Nov 2025 454.45 453.15
13 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Feb 2026 439.55 464.00
14 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 May 2026 557.20 540.35
03 Jul 2026 DIVIDEND Dividend
1.00 /share
03 Jul 2026 540.35 637.45
03 Jul 2026 DIVIDEND Dividend
2.00 /share
03 Jul 2026 540.35 637.45
10 Jul 2026 ANNUAL GENERAL MEETING Annual General Meeting
NA
10 Jul 2026 540.35 658.00
08 Aug 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 Aug 2026 667.45 697.45

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation19 hrs ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome21 hrs ago
Newspaper Publication21 hrs ago
Monitoring Agency Report22 hrs ago
Announcement under Regulation 30 (LODR)-Investor Presentation2 days ago
Press Release2 days ago
Un-Audited Financial Results For The Quarter Ended 30Th June 20262 days ago
Board Meeting Outcome for Un-Audited Financial Results For The Quarter Ended 30Th June 20262 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
Board Meeting Intimation for Un-Audited (Standalone & Consolidated) Financial Results For The Quarter Ended On 30Th June 20265 days ago
Announcement under Regulation 30 (LODR)-AcquisitionJul 23, 2026
Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 11, 2026
Shareholder Meeting / Postal Ballot-Outcome of AGMJul 10, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2026
Update On Penalty Imposed By The Deputy Commissioner Of State Tax Gujarat On Maxcure Nutravedics Limited Wholly Owned Subsidiary Of The CompanyJul 04, 2026
Closure of Trading WindowJun 25, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 19, 2026
Notice And Integrated Annual Report For The Financial Year 2025-26 To Those Members Who Have Not Registered Their E-Mail IDSJun 19, 2026
Business Responsibility and Sustainability Reporting (BRSR)Jun 18, 2026
Reg. 34 (1) Annual Report.Jun 18, 2026
Notice Of The 22Nd Annual General MeetingJun 18, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 16, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 10, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 09, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 03, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 28, 2026
Receipt Of Assessment Order(S) By Certain Subsidiaries From Income Tax DepartmentMay 22, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 21, 2026
Receipt Of Assessment Order(S) From Income Tax DepartmentMay 20, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 18, 2026
Update On Disruption In Operations At Some Of The Manufacturing Sites At HaridwarMay 18, 2026
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 16, 2026
Update On Disruption In Operations At Some Of The Manufacturing Sites At HaridwarMay 16, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationMay 14, 2026
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 14, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2026
Intimation Of Disruption In Operations At Some Of The Manufacturing Sites At HaridwarMay 14, 2026
Corporate Action-Board approves DividendMay 14, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMay 14, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMay 14, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMay 14, 2026
Financial Results For The Quarter And Year Ended 31St March 2026May 14, 2026
Recommendation Of Final Cum Special DividendMay 14, 2026
Board Meeting Outcome for Outcome Of Board Meeting For Financial ResultsMay 14, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 12, 2026
Board Meeting Intimation for Board Meeting IntimationMay 11, 2026
ESG RatingMay 08, 2026
Execution Of Lease DeedApr 29, 2026

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
JioBlackRock Flexi Cap Fund Direct-Growth
0.00%
-156708
-0.30%
-0.36%
Old Bridge Flexi Cap Fund Direct-Growth
0.00%
-76000
-2.26%
-2.26%
Franklin India Multi-Factor Fund Direct-Growth
0.00%
-18658
-0.20%
-0.28%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.00%
-104
-0.01%
-0.01%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth
1.89%
0
0.00%
-0.16%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.00%
0
0.00%
-0.01%
Bandhan Small Cap Fund Direct-Growth
0.38%
0
0.00%
-0.01%
DSP Nifty 500 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
DSP Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
Edelweiss Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
Edelweiss Recently Listed IPO Fund Direct-Growth
0.00%
0
0.00%
0.00%
Franklin India Multi Cap Fund Direct-Growth
1.35%
0
0.00%
-0.15%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
Franklin India Opportunities Direct Fund-Growth
1.78%
0
0.00%
0.00%
Franklin India Small Cap Fund Direct-Growth
0.96%
0
0.00%
0.00%
Groww Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
Groww Nifty Total Market Index Fund Direct-Growth
0.00%
0
0.00%
-0.01%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
ICICI Prudential ELSS Tax Saver Direct Plan-Growth
0.64%
0
0.00%
-0.09%
ICICI Prudential Equity & Debt Fund Direct-Growth
0.00%
0
0.00%
-0.12%
ICICI Prudential Multi Asset Fund Direct-Growth
0.00%
0
0.00%
0.00%
ICICI Prudential Nifty 500 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
JioBlackRock Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
69.39
ATR(14)
Volatile
24.48
STOCH(9,6)
Neutral
48.35
STOCH RSI(14)
Neutral
57.00
MACD(12,26)
Bullish
0.51
ADX(14)
Strong Trend
36.67
UO(9)
Bearish
55.94
ROC(12)
Uptrend And Accelerating
4.91
WillR(14)
Neutral
-25.91

About Akums Drugs & Pharma

Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) established in 2004. The company offers a wide range of pharmaceutical products and services both domestically and internationally. Their operations include manufacturing of Active Pharmaceutical Ingredients (APIs), sale of branded pharmaceutical formulations, formulation research and...more
Listing Date
06 Aug, 2024(2 Years, 5 Days)